Schafhauser W, Ebert A, Brod J, Petsch S, Schrott K M
Department of Urology, University of Erlangen-Nürnberg, Germany.
Anticancer Res. 1999 Mar-Apr;19(2C):1573-8.
The value of systematic lymphadenectomy has been a matter of great controversy for a long period of time. A recently published paper of a retrospective autopsy study generally doubts its therapeutic effectiveness, arguing that positive lymph nodes are nearly always associated with distant metastases.
Between 1974 and 1993 1035 patients suffering from renal cell carcinoma with stages from cT 1 to 4, cM 0 were treated with curative intention. 51% underwent radical abdominal tumour nephrectomy with systematic lymphadenectomy (n = 531, group A). In 199 patients (19%, group B) only macroscopically suspect lymph nodes were removed surgically. All other patients underwent radical lumbar tumour nephrectomy without lymphadenectomy (n = 305, 29%, group C).
Mean age of group A was 55.5 +/- 10 years, B 60.3 +/- 11 and C 66.5 +/- 11. Median follow-up for all groups was 115 +/- 63 months. Median amount of removed lymph nodes was 18 in group A, 6 in group B and 3 in group C. N-categories for each group were pN 1: 4%, 2%, 1%; pN 2: 7%, 5%, 1%; pN 3: 3%, 2, %, 1%; pN x: 0%, 35%, 67% respectively. Group A with systematic lymphadenectomy had the least favourable tumour stage overall. Nevertheless long-term survival of this group is more favourable with 57% +/- 6 when compared to group B with 50 +/- 12% and C with 44% +/- 9%. 20 (27%) of the 75 lymph node positive patients of group A who have been followed-up for more than 5 years are still alive.
At least 4% of all patients benefit from extensive lymphadenectomy. This may only be a relatively small proven effect for the entire patient collective, but for a single lymph node positive patient this is an undoubtedly significant additional chance of survival especially when one notes that presently there is no curative adjuvant therapy.
系统性淋巴结清扫术的价值长期以来一直存在很大争议。最近发表的一篇回顾性尸检研究论文普遍质疑其治疗效果,认为阳性淋巴结几乎总是与远处转移相关。
1974年至1993年间,1035例cT1至4期、cM0的肾细胞癌患者接受了根治性治疗。51%的患者接受了根治性腹部肿瘤肾切除术及系统性淋巴结清扫术(n = 531,A组)。199例患者(19%,B组)仅手术切除了肉眼可疑的淋巴结。所有其他患者接受了根治性腰部肿瘤肾切除术,未进行淋巴结清扫术(n = 305,29%,C组)。
A组的平均年龄为55.5±10岁,B组为60.3±11岁,C组为66.5±11岁。所有组的中位随访时间为115±63个月。A组切除的淋巴结中位数为18个,B组为6个,C组为3个。每组的N分期为:pN1分别为4%、2%、1%;pN2分别为7%、5%、1%;pN3分别为3%、2%、1%;pNx分别为0%、35%、67%。进行系统性淋巴结清扫术的A组总体肿瘤分期最不理想。然而,该组的长期生存率更有利,为57%±6%,相比之下,B组为50%±12%,C组为44%±9%。A组75例淋巴结阳性患者中,有20例(27%)接受了超过5年的随访,仍然存活。
至少4%的患者可从广泛的淋巴结清扫术中获益。这对整个患者群体来说可能只是一个相对较小的已证实的效果,但对于单个淋巴结阳性患者来说,这无疑是一个显著的额外生存机会,尤其是考虑到目前尚无根治性辅助治疗。